AI medical trial: AstraZeneca evaluates "AI pathology" in real-world lung and breast cancer practice (multinational, observational)
A multinational observational study by AstraZeneca evaluating how computational pathology plus AI algorithms are used in the pathology workup of patients with suspected lung and breast cancer — gauging how far AI has entered routine pathology.
Trial overview (primary data)
- StatusActive, not recruiting
- ConditionsLung Cancer, Breast Cancer
- SponsorAstraZeneca
- Target enrollment600 participants
- Period2025-10-25 〜 2027-05-31
Key points
- AstraZeneca evaluates real-world use of AI (computational pathology) in lung/breast cancer pathology
- An observational study of adoption, not a new-tool performance test
- Relevant to patient selection (biomarker assessment) for cancer therapies
- Multinational, 600 participants, 2025–2027, active (not recruiting)
AstraZeneca's clinical study (NCT06827132) evaluates how AI is used in real-world practice in the pathology workup of patients with suspected lung and breast cancer — a multinational observational study.
Per the registry summary, the goal is to evaluate "the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer." It is observational (no intervention), with target enrollment 600 and a period of October 25, 2025 – May 31, 2027; status as of the check date is active, not recruiting.
Pathology — examining tissue under the microscope to confirm cancer type — is central to oncology. Increasingly, slides are digitized (digital pathology) and AI algorithms assist with region extraction, classification, and quantification (computational pathology). Rather than testing a new tool's performance, this study characterizes how AI pathology is actually adopted into clinical workflow, from a pharmaceutical-company perspective (relevant to patient selection / biomarker assessment for cancer therapies).
Why it matters
AI pathology is an area of regulatory approval and adoption in many markets. A major pharma company systematically characterizing its real-world use is a useful read on AI penetration in oncology and on AI for companion diagnostics / patient selection.
FAQ
What is computational (AI) pathology?
Is this a new AI performance trial?
Sources (primary)
Source: ClinicalTrials.gov (U.S. NIH/NLM, public domain). This site does not provide medical advice. Verify the latest and exact details with the official source. This site is not endorsed or certified by the NIH/NLM.
- ClinicalTrials.gov (study record, original)
- NCT ID: NCT06827132